Dentists, antibiotics and Clostridium difficile-associated disease

British Dental Journal

Volumn 219, Issue 6, 2015, Pages 275-279

  Beacher, N ^a   Sweeney, M P ^a   Bagg, J ^a  

^a GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADVERSE EFFECTS; ATTITUDE TO HEALTH; CLINICAL PRACTICE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GREAT BRITAIN; HUMAN; INAPPROPRIATE PRESCRIBING; PEPTOCLOSTRIDIUM DIFFICILE; PREVENTION AND CONTROL; STATISTICS AND NUMERICAL DATA;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GREAT BRITAIN; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INAPPROPRIATE PRESCRIBING; PRACTICE PATTERNS, DENTISTS';

EID: 84942568955     PISSN: 00070610     EISSN: 14765373     Source Type: Journal    
DOI: 10.1038/sj.bdj.2015.720     Document Type: Article

References (95)

1. Ramsay G. Prescribing by dentists: England 2013. London: Health and Social Care Information Centre; 2014. Available online at http://www.hscic.gov.uk/catalogue/PUB14016/pres-dent-eng-2013-rpt.pdf (accessed September 2015
2. Karki A.J, Holyfield G, Thomas D. Dental prescribing in Wales and associated public health issues. Br Dent J. 2011; 210: E21.
3. Seymour R.A. Antibiotics in dentistry - An update. Dent Update. 2013; 40: 319-322.
4. ten Cate J.M, Zaura E. The numerous microbial species in oral biofilms: how could antibacterial therapy be effective? Adv Dent Res. 2012; 24: 108-111.
5. Saini R, Saini S, Sharma S. Biofilm: A dental microbial infection. J Nat Sci Biol Med. 2011; 2: 71-75.
6. Tulip D.E, Palmer N.O A retrospective investigation of the clinical management of patients attending an out of hours dental clinic in Merseyside under the new NHS dental contract. Br Dent J. 2008; 205: 659-664.
7. Dailey Y.M, Martin M.V. Are antibiotics being used appropriately for emergency dental treatment? Br Dent J. 2001; 191: 391-393.
8. Cherry W.R, Lee J.Y, Shugars D.A, White R.P, Jr., Vann W.F, Jr. Antibiotic use for treating dental infections in children: a survey of dentists'prescribing practices. J Am Dent Assoc. 2012; 143: 31-38.
9. Dar-Odeh N.S, Abu-Hammad O.A, Al-Omiri M.K, Khraisat A.S, Shehabi A.A. Antibiotic prescribing prac-Tices by dentists: a review. Ther Clin Risk Management. 2010; 6: 301-306.
10. Kudiyirickal M.G, Hollinshead F. Antimicrobial prescrib-ing practice by dentists: a study from two primary care centres in UK. Minerva Stomatol. 2011; 60: 495-500.
11. Carter L.M, Layton S. Cervicofacial infection of dental origin presenting to maxillofacial surgery units in the United Kingdom: a national audit. Br Dent J. 2009; 206: 73-78.
12. Richey R, Wray D, Stokes T, Guideline Development G. Prophylaxis against infective endocarditis: summary of NICE guidance. BMJ. 2008; 336: 770-771.
13. Zimmerli W, Sendi P. Antibiotics for prevention of periprosthetic joint infection following dentistry: time to focus on data. Clin Infect Dis. 2010; 50: 17-19.
14. Antimicrobial resistance: global report on sur-veillance: World Health Organization, 2014. Available online at http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748-eng.pdf?ua+1 (accessed September 2015
15. Stryjewski M.E, Corey G.R. Methicillin-resistant Staphylococcus aureus: an evolving pathogen. Clin Infect Dis. 2014; 58 (Suppl 1): S10-19.
16. Hawker J.I, Smith S, Smith G.E, et al. Trends in antibiotic prescribing in primary care for clinical syndromes sub-ject to national recommendations to reduce antibiotic resistance, UK 1995-2011: analysis of a large database of primary care consultations. J Antimicrob Chemother. 2014; 69: 3423-3430.
17. Kazanowski M, Smolarek S, Kinnarney F, Grzebieniak Z. Clostridium difficile: epidemiology, diagnostic and therapeutic possibilitiesa systematic review. Tech Coloproctol. 2014; 18: 223-232.
18. Aroori S, Blencowe N, Pye G, West R. Clostridium diffi-cile: how much do hospital staff know about it? Ann R Coll Surg Engl. 2009; 91: 464-469.
19. Burnett E, Kearney N, Johnston B, Corlett J, MacGillivray S. Understanding factors that impact on health care professionals'risk perceptions and responses toward Clostridium difficile and meticil-lin-resistant Staphylococcus aureus: a structured liter-Ature review. Am J Infect Control. 2013; 41: 394-400.
20. Kyne L, Hamel M.B, Polavaram R, Kelly C.P. Health care costs and mortality associated with nosocomial diarrhoea due to Clostridium difficile. Clin Infect Dis. 2002; 34: 346-353.
21. Havard D.B, Ray J.M. How can we as dentists minimize our contribution to the problem of antibiotic resistance? Oral Maxillofac Surg Clin North Am. 2011; 23: 551-555.
22. Swift J.Q, Gulden W.S. Antibiotic therapy managing odontogenic infections. Dent Clin North Am. 2002; 46: 623-633.
23. Mainjot A, D'Hoore W, Vanheusden A, Van Nieuwenhuysen J.P. Antibiotic prescribing in den-Tal practice in Belgium. Int Endod J. 2009; 42: 1112-1117.
24. Slimings C, Riley T.V. Antibiotics and hospital-Ac-quired Clostridium difficile infection: update of systematic review and meta-Analysis. J Antimicrob Chemother. 2014; 69: 881-891.
25. Prior M, Elouafkaoui, Elders A, Young L, Duncan E.M, Newlands R, et al. Evaluating an audit and feedback intervention for reducing antibiotic prescribing behaviour in general dental practice (the RAPiD trial): a partial factorial cluster randomised trial protocol. Implement Sci. 2014; 9: 50.
26. Löffler C, Böhmer F, Hornung A, et al. Dental care resistance prevention and antibiotic prescribing mod-ification-The cluster-randomised controlled DREAM trial. Implement Sci. 2014; 9: 27.
27. Cope A.L, Wood F, Francis N.A, Chestnutt I.G. General dental practitioners'perceptions of antimicrobial use and resistance: a qualitative interview study. Br Dent J 2014 Sep; 217: E9.
28. Thornhill M.H, Dayer M.J, Forde J.M, et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ. 2011; 342: d2392.
29. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infec-Tive endocarditis in England, 2000-2013: a secular trend, interrupted time-series analysis. Lancet. 2015; 385: 1219-1228.
30. Roy K.M, Smith A, Sanderson J, et al. Barriers to the use of a diagnostic oral microbiology laboratory by general dental practitioners. Br Dent J. 1999; 186: 345-347.
31. Rams T.E, Degener J.E, van Winkelhoff A.J. Antibiotic resistance in human chronic periodontitis microbiota. J Periodontol. 2014; 85: 160-169.
32. Rocas I.N, Siqueira J.F, Jr. Detection of antibiotic resistance genes in samples from acute and chronic endodontic infections and after treatment. Arch Oral Biol. 2013; 58: 1123-1128.
33. Kim S.M, Kim H.C, Lee S.W. Characterization of antibiotic resistance determinants in oral biofilms. J Microbiol. 2011; 49: 595-602.
34. Fanaro S, Chierici R, Guerrini P, Vigi V. Intestinal micro-flora in early infancy: composition and development. Acta Paediatr Suppl. 2003; 91: 48-55.
35. Sullivan A, Edlund C, Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001; 1: 101-114.
36. Vedantam G, Clark A, Chu M, McQuade R, Mallozzi M, Viswanathan V.K. Clostridium difficile infection: toxins and non-Toxin virulence factors, and their contribu-Tions to disease establishment and host response. Gut microbes. 2012; 3: 121-134.
37. Hall C, O'Toole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child. 1935; 49: 390-402.
38. George W.L, Rolfe R.D, Sutter V.L, Finegold S.M. Diarrhoea and colitis associated with antimicrobial therapy in man and animals. Am J Clin Nutr. 1979; 32: 251-257.
39. Rifkin G.D, Fekety F.R, Silva J, Jr. Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin. Lancet. 1977; 2: 1103-1106.
40. George W.L, Sutter V.L, Finegold S.M. Antimicrobial agent-induced diarrhoea - A bacterial disease. J Infect Dis. 1977; 136: 822-828.
41. Larson H.E, Price A.B. Pseudomembranous colitis: Presence of clostridial toxin. Lancet. 1977; 2: 1312-1314.
42. Bartlett J.G, Chang T.W, Gurwith M, Gorbach S.L, Onderdonk A.B. Antibiotic-Associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978; 298: 531-534.
43. George R.H, Symonds J.M, Dimock F, et al. Identification of Clostridium difficile as a cause of pseudomembra-nous colitis. BMJ. 1978; 1: 695.
44. George W.L, Sutter V.L, Goldstein E.J, Ludwig S.L, Finegold S.M. Aetiology of antimicrobial-Agent-Associated colitis. Lancet. 1978; 1: 802-803.
45. Tedesco F.J. Clindamycin and colitis: a review. J Infect Dis. 1977; 135 (Suppl): S95-98.
46. Bartlett J.G. Narrative review: the new epidemic of Clostridium difficile-Associated enteric disease. Ann Intern Med. 2006; 145: 758-764.
47. Shen A. Clostridium difficile toxins: mediators of inflammation. J Innate Immun. 2012; 4: 149-158.
48. Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, Aktories K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature. 1995; 375: 500-503.
49. Lyerly D.M, Saum K.E, MacDonald D.K, Wilkins T.D. Effects of Clostridium difficile toxins given intragastri-cally to animals. Infect Immun. 1985; 47: 349-352.
50. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005; 366: 1079-1084.
51. Brazier J.S, Patel B, Pearson A. Distribution of Clostridium difficile PCR ribotype 027 in British hospi-Tals. Euro Surveill. 2007; 12: E070426.2.
52. Kuijper E.J, Barbut F, Brazier J.S, et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill. 2008; 13(31
53. Clements A.C, Magalhaes R.J, Tatem A.J, Paterson D.L, Riley TV. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis. 2010; 10: 395-404.
54. Carroll K.C, Bartlett J.G. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol. 2011; 65: 501-521.
55. Schwan C, Stecher B, Tzivelekidis T, et al. Clostridium difficile toxin CDT induces formation of microtu-bule-based protrusions and increases adherence of bacteria. PLoS Pathogens. 2009; 5: e1000626.
56. Valiente E, Dawson L.F, Cairns M.D, Stabler R.A, Wren B.W. Emergence of new PCR ribotypesfrom the hypervirulent Clostridium difficile 027 lineage. J Med Microbiol. 2012; 61: 49-56.
57. Wilcox M, Public Health England. Clostridium difficile Ribotyping Network (CDRN) for England and Northern Ireland 2011-2013 Report. Available online at https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/329: 156/C-difficile-ribotyp-ing
58. Walk S.T, Micic D, Jain R, et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis. 2012; 55: 1661-1668.
59. Tenover F.C, Tickler I.A, Persing D.H. Antimicrobial-resistant strains of Clostridium difficile from North America. Antimicrob Agents Chemother. 2012; 56: 2929-2932.
60. Dunne M, Mertens H.D, Garefalaki V, et al. The CD27L and CTP2XXXXX1L endolysins targeting clostridia contain a built-in trigger and release factor. PLoS Pathogens. 2014; 10: e1004228.
61. Mulcahy L. Deaths involving Clostridium difficile, England and Wales, 2012. Office for National Statistics, 2013. Available online at http://www.ons.gov.uk/ons/dcp171778-323989.pdf (accessed September 2015
62. Duerden BI. Contribution of a government target to controlling Clostridium difficile in the NHS in England. Anaerobe. 2011; 17: 175-179.
63. Barbut F, Petit J.C. Epidemiology of Clostridium diffi-cile-Associated infections. Clin Microbiol Infect. 2001; 7: 405-410.
64. Khanna S, Pardi D.S. Community-Acquired Clostridium difficile infection: an emerging entity. Clin Infect Diseases. 2012; 55: 1741-1742.
65. Khanna S, Pardi D.S, Aronson S.L, et al. The epidemi-ology of community-Acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012; 107: 89-95.
66. Fekety R, Kim K.H, Batts D.H, et al. Studies on the epidemiology of antibiotic-Associated Clostridium difficile colitis. Am J Clinical Nutr. 1980; 33(11 Suppl): 2527-2532.
67. Mulligan M.E, George W.L, Rolfe R.D, Finegold S.M. Epidemiological aspects of Clostridium difficile-induced diarrhoea and colitis. Am J Clinical Nutr. 1980; 33(11 Suppl): 2533-2538.
68. Kim K.H, Fekety R, Batts D.H, et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-Associated colitis. J Infectious Dis. 1981; 143: 42-50.
69. Testore G.P, Pantosti A, Cerquetti M, Babudieri S, Panichi G, Gianfrilli P.M. Evidence for cross-infection in an outbreak of Clostridium difficile-Associated diarrhoea in a surgical unit. J Med Microbiol. 1988; 26: 125-128.
70. Malamou-Ladas H, O'Farrell S, Nash J.Q, Tabaqchali S. Isolation of Clostridium difficile from patients and the environment of hospital wards. J Clin Pathol. 1983; 36: 88-92.
71. Nolan N.P, Kelly C.P, Humphreys J.F, et al. An epidemic of pseudomembranous colitis: importance of person to person spread. Gut. 1987; 28: 1467-1473.
72. McFarland L.V, Mulligan M.E, Kwok R.Y, Stamm W.E. Nosocomial acquisition of Clostridium difficile infec-Tion. N Engl J Med. 1989; 320: 204-210.
73. Gerding D.N, Muto C.A, Owens R.C, Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis. 2008; 46 (Suppl 1): S43-49.
74. Burns D.A, Heap J.T, Minton N.P. Clostridium difficile spore germination: an update. Res Microbiol. 2010; 161: 730-734.
75. Hensgens M.P, Keessen E.C, Squire M.M, et al. Clostridium difficile infection in the community: a zoo-notic disease? Clin Microbiol Infect. 2012; 18: 635-645.
76. Vega O.G, Janus C, Laskin D.M. Hand-washing knowledge and practices among dentists and dental specialists. Quintessence Int. 2012; 43: 429-434.
77. Oughton M.T, Loo V.G, Dendukuri N, Fenn S, Libman M.D. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile. Infect Control Hosp Epidemiol. 2009; 30: 939-944.
78. Rutala W.A, Gergen M.F, Weber D.J. Efficacy of different cleaning and disinfection methods against Clostridium difficile spores: importance of physical removal versus sporicidal inactivation. Infect Control Hosp Epidemiol. 2012; 33: 1255-1258.
79. Macleod-Glover N, Sadowski C. Efficacy of cleaning products for C. difficile: environmental strategies to reduce the spread of Clostridium difficile-Associated diarrhoea in geriatric rehabilitation. Can Fam Physician. 2010; 56: 417-423.
80. Surawicz CM. Clostridium difficile infection: risk factors, diagnosis and management. Curr Treat Options Gastroenterol. 2015; 13: 121-129.
81. Blossom D.B, Lewis F.M, McDonald L.C. The changing spectrum of Clostridium difficile associated disease: implications for dentistry. J Am Dent Assoc. 2008; 139: 42-47.
82. Owens R C Jr, Donskey C.J, Gaynes R.P, Loo V.G, Muto C.A. Antimicrobial-Associated risk fac-Tors for Clostridium difficile infection.Clin Infect Dis. 2008; 46 (Suppl 1): S19-31.
83. Addy L.D, Martin M.V. Clindamycin and dentistry. Br Dent J. 2005; 199: 23-26.
84. Salvo F, De Sarro A, Caputi A.P, Polimeni G. Amoxicillin and amoxicillin plus clavulanate: a safety review. Exp Opin Drug Safety. 2009; 8: 111-118.
85. Kelly C.P, LaMont JT. Clostridium difficile infection. Annu Rev Med. 1998; 49: 375-390.
86. Wilcox M, Public Health England. Updated guidance on the management and treatment of Clostridium difficile infection. May 2013. Available online at https://www.gov.uk/government/publications/clostridium-diffi-cile-infection-guidance-on-management-And-Treat-ment (accessed September 2015
87. De Silva M. Updated guidance on the diagnosis and reporting of Clostridium difficile. UK Department of Health, 2012. Available online at https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/215135/dh-133016.pdf (accessed September 2015
88. Burkart N.E, Kwaan M.R, Shepela C, et al. Indications and relative utility of lower endoscopy in the manage-ment of Clostridium difficile infection. Gastroenterol Res Pract. 2011; 626: 582.
89. Gillon R. Medical ethics: four principles plus attention to scope. BMJ. 1994; 309: 184-188.
90. Hansen D, Pollan L.D, Fernando H. Fulminant Clostridium difficile colitis: a complication of periop-erative antibiotic prophylaxis. J Oral Maxillofac Surg. 2013; 71: 1880-1885.
91. Chate R.A, White S, Hale L.R, et al. The impact of clinical audit on antibiotic prescribing in general den-Tal practice. Br Dent J. 2006; 201: 635-641.
92. Palmer N.A, Dailey Y.M, Martin M.V. Can audit improve antibiotic prescribing in general dental practice? Br Dent J. 2001; 191: 253-255.
93. Borde J.P, Kaier K, Steib-Bauert M, et al. Feasibility and impact of intensified anti-biotic stewardship programme target-ing cephalosporin andfluoroquinolone use in a tertiary care university medical centre. BMC Infect Dis. 2014; 14: 201. .
94. Weber D.J, Anderson D.J, Sexton D.J, Rutala W.A. Role of the environment in the transmission of Clostridium difficile in health care facilities. Am J Infect Control. 2013; 41(5 Suppl): S105-110.
95. Eklund K.J. Infection control. Dent Clin N Am. 2003; 47: 697-708.